Onconic Therapeutics Officially Invited to JP Morgan Healthcare Conference for Second Consecutive Year

Onconic Therapeutics announced on December 11 that it has been officially invited for the second consecutive year to participate in the '2026 JP Morgan Healthcare Conference,' which will be held in San Francisco, USA, from January 12 to 15, 2026 (local time).

The JP Morgan Healthcare Conference is the largest healthcare investment event in the industry, held every January at the Westin St. Francis hotel in San Francisco. Major global pharmaceutical companies, biotech firms, and investors from around the world participate in large numbers.

원본보기 아이콘

An official invitation to this event serves as a form of 'certification effect,' recognizing a company's technological capabilities and growth potential on the global stage. In particular, because only companies invited by JP Morgan can attend this exclusive event, this consecutive invitation is seen as reaffirming the overseas market’s trust in the company’s technological competitiveness.

The key factor behind Onconic Therapeutics’ consecutive invitation appears to be the research and clinical achievements of its next-generation synthetic lethal dual-targeted anticancer drug candidate, 'Nesuparib.' Since first presenting multi-cancer Phase 1 clinical data at the 2021 ASCO (American Society of Clinical Oncology), Onconic Therapeutics has announced a total of seven clinical presentations related to Nesuparib at major international cancer conferences, including the AACR (American Association for Cancer Research) and ASCO, by presenting follow-up research and clinical results every year.

Onconic Therapeutics is positively evaluated for steadily raising awareness and credibility within the global academic and industry communities through presentations at multiple international conferences prior to its listing, highlighting Nesuparib’s differentiated mechanism of action and stable research and clinical data.

Additionally, the company is highly regarded in the global investment and industry sectors for being one of the few domestic biotech firms to have completed its own Phase 3 clinical trial and directly obtained new drug approval.

Nesuparib is a first-in-class anticancer drug candidate that simultaneously inhibits PARP-1/2 and Tankyrase-1/2, offering a differentiated mechanism that addresses resistance to existing PARP inhibitors and the issue of Wnt signaling activation.

Currently, Phase 2 clinical trials are underway for pancreatic cancer and endometrial cancer, both of which have high unmet medical needs. The company received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for pancreatic cancer in 2021, and for gastric cancer and gastroesophageal junction cancer earlier this year.

During the conference, Onconic Therapeutics plans to hold a series of meetings with various partners, including global pharmaceutical companies, biotech firms, and healthcare-focused investment institutions, to advance its global expansion. In particular, the company will broadly discuss technological collaboration and commercialization opportunities, focusing on the latest research achievements of Nesuparib.

A representative from Onconic Therapeutics stated, "Being officially invited for two consecutive years since our listing is a meaningful achievement that demonstrates the global recognition of Onconic Therapeutics’ capabilities in new drug R&D, as well as the innovativeness of our anticancer drug candidate Nesuparib and the P-CAB new drug Jakubo. With the momentum for Nesuparib's development strengthening, including the recent initiation of patient enrollment and dosing for the Phase 2 pancreatic cancer trial, we expect this conference to serve as a platform to share our development direction and expand discussions on collaboration with major overseas companies."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.